الإحصائيات الأساسية
| CIK | 1837821 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Jin Medical International Ltd.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on September 3, 2025 As filed with the U.S. Securities and Exchange Commission on September 3, 2025 Registration No. 333-288314 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jin Medical International Ltd. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant’s name in |
|
| September 3, 2025 |
Exhibit 4.1 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL LTD. (adopted by a Special Resolution passed on 22 December 2022 and effective immediately prior to the completion of the Company’s initial public offering of Ordinary Shares) 1. The name of the Company is JIN MEDICAL INTERNATIONAL L |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu |
|
| August 20, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion of the financial condition and results of operations is based upon and should be read in conjunction with the unaudited financial results and statements of Jin Medical International Ltd. (the “Company,” “we,” “our,” or “us”) for the six (6) months ended March 31, 2025, furnished as Exhibit 99.1. to this report. Over |
|
| August 20, 2025 |
JIN MEDICAL INTERNATIONAL LTD. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Exhibit 99.1 JIN MEDICAL INTERNATIONAL LTD. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS March 31, September 30, 2025 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 11,131,890 $ 8,136,179 Short-term investments 19,824,675 18,621,251 Accounts receivable, net 4,238,724 5,912,035 Accounts receivable - related parties 1,385,555 2,546,358 Inventories 4,455,065 5,173,458 Due from related parties 137, |
|
| July 16, 2025 |
Exhibit 99.1 Jin Medical Launches Production at Plant No. 3, Accelerating Global Delivery from the Chuzhou Manufacturing Facility Beijing, China, July 16, 2025 (GLOBE NEWSWIRE) - Jin Medical International Ltd. (Nasdaq: ZJYL) (“Jin Medical”, and together with all its subsidiaries, the “Company”), a Nasdaq-listed provider of rehabilitation medical equipment, announced today that its wholly owned sub |
|
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-41661 Jin Medical International Ltd. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu P |
|
| June 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 25, 2025 As filed with the U.S. Securities and Exchange Commission on June 25, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jin Medical International Ltd. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Cayman Islands N/ |
|
| June 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Jin Medical International Ltd. |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-41661 Jin Medical International Ltd. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu P |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-41661 Jin Medical International Ltd. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu P |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-41661 Jin Medical International Ltd. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Pr |
|
| May 6, 2025 |
Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance Exhibit 99.1 Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) - Jin Medical International Ltd. (NASDAQ: ZJYL) (the “Company”) today announced that on May 2, 2025, it received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”). The No |
|
| April 25, 2025 |
Exhibit 99.1 Jin Medical Accelerates Chuzhou Facility Construction to Unlock Annual Production Capacity of RMB 300 Million Chuzhou City, China, April 24, 2025 (GLOBE NEWSWIRE) - Jin Medical International Ltd. (Nasdaq:ZJYL), a Nasdaq-listed provider of rehabilitation medical equipment, announced today that its wholly owned subsidiary, Jin Medical Equipment (Anhui) Co., Ltd., has made significant pr |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu |
|
| March 20, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ziqiang Wang, Chief Financial Officer of Jin Medical International Ltd. (the “Company”), certify that: 1. I have reviewed this annual report on Form 20-F, as amended by Amendment No. 1 thereto, of the Company; 2. Based on my knowledge, this report does not contain any untrue s |
|
| March 20, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Erqi Wang, Chief Executive Officer of Jin Medical International Ltd. (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: a. the Company’s annual report on F |
|
| March 20, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Erqi Wang, Chief Executive Officer of Jin Medical International Ltd. (the “Company”), certify that: 1. I have reviewed this annual report on Form 20-F, as amended by Amendment No. 1 thereto, of the Company; 2. Based on my knowledge, this report does not contain any untrue stat |
|
| March 20, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Ziqiang Wang, Chief Financial Officer of Jin Medical International Ltd. (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: a. the Company’s annual report o |
|
| March 20, 2025 |
Jin Medical International Ltd. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China March 20, 2025 Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.C. 20549 Attn: Julie Sherman and Kristin Lochhead Re: Jin Medical International Ltd. Form 20-F for Fiscal Year En |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE |
|
| January 24, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ziqiang Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Jin Medical International Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements ma |
|
| January 24, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Erqi Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Jin Medical International Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| January 24, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Jin Medical International Ltd. (the “Company”) on Form 20-F for the year ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Erqi Wang, Chief Executive Officer of the Company, |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 |
|
| January 24, 2025 |
Beijing Dacheng Law Offices, LLP (Shanghai) Consent Letter Exhibit 15.2 Beijing Dacheng Law Offices, LLP (Shanghai) Consent Letter January 24, 2025 To: Jin Medical International Ltd. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China Dear Sir/Madam, We hereby consent to the references to our firm’s name in Jin Medical International Ltd.’s annual report on Form 20-F for the year ended September 30, 2024 (the “ |
|
| January 24, 2025 |
Exhibit 15.1 Our ref SQG/780862-000001/31250853v1 JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China 24 January 2025 Dear Sirs JIN MEDICAL INTERNATIONAL LTD. We have acted as legal advisers as to the laws of the Cayman Islands JIN MEDICAL INTERNATIONAL LTD., an exempted company incorporated in the Cayman Islands with lim |
|
| January 24, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Jin Medical International Ltd. (the “Company”) on Form 20-F for the year ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ziqiang Wang, Chief Financial Officer of the Compan |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangs |
|
| October 11, 2024 |
Construction of JinMed’s New Facility Begins in Chuzhou, China Exhibit 99.1 Construction of JinMed’s New Facility Begins in Chuzhou, China Chuzhou City, China, Oct. 10, 2024 (GLOBE NEWSWIRE) - JIN MEDICAL INTERNATIONAL LTD. (the “Company” or “JinMed”) (NASDAQ: ZJYL), an industrial leader in Assistive Technologies (“AT”), and a manufacturer and developer of wheelchairs and living aids products, today announced the initiation of construction of JinMed’s new man |
|
| July 26, 2024 |
Exhibit 99.1 JIN MEDICAL INTERNATIONAL LTD. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS March 31, September 30, 2024 2023 (Unaudited) ASSETS CURRENT ASSETS: Cash $ 8,874,902 $ 6,929,508 Short-term investments 17,113,103 9,768,835 Accounts receivable, net 3,856,529 3,283,266 Accounts receivable - related parties 1,524,570 94 |
|
| July 26, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion of the financial condition and results of operations is based upon and should be read in conjunction with the unaudited financial results and statements of Jin Medical International Ltd. (the “Company,” “we,” “our,” or “us”) for the six (6) months ended March 31, 2024, furnished as Exhibit 99.1. to this report. Over |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu P |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Pr |
|
| April 26, 2024 |
Beijing Dacheng Law Offices, LLP (Shanghai) Consent Letter Exhibit 15.2 Beijing Dacheng Law Offices, LLP (Shanghai) Consent Letter April 26, 2024 To: Jin Medical International Ltd. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China Dear Sir/Madam, We hereby consent to the references to our firm’s name in Jin Medical International Ltd.’s annual report on Form 20-F for the year ended September 30, 2023 (the “An |
|
| April 26, 2024 |
JIN MEDICAL INTERNATIONAL LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97.1 JIN MEDICAL INTERNATIONAL LTD. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION In accordance with the applicable rules of The Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Jin Medical International Ltd. (the “Company”) has adopt |
|
| April 26, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Erqi Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Jin Medical International Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 26, 2024 |
Jin Medical International Ltd. Insider Trading Policy Exhibit 11.2 Jin Medical International Ltd. Insider Trading Policy This Insider Trading Policy, adopted as of January 26, 2024 (this “Policy”), describes the standards of Jin Medical International Ltd. and its subsidiaries (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies while in possession of confidential inf |
|
| April 26, 2024 |
JIN MEDICAL INTERNATIONAL LTD. Exhibit 15.1 Our ref SQG/780862-000001/28529836v1 JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China April 26, 2024 Dear Sirs JIN MEDICAL INTERNATIONAL LTD. We have acted as legal advisers as to the laws of the Cayman Islands JIN MEDICAL INTERNATIONAL LTD., an exempted company incorporated in the Cayman Islands with limi |
|
| April 26, 2024 |
Exhibit 1.2 THE COMPANIES ACT (AS REVISED) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL LTD. (adopted by a Special Resolution passed on 22 December 2022 and effective immediately prior to the completion of the Company’s initial public offering of Ordinary Shares) 1. The name of the Company is JIN MEDICAL INTERNATIONAL L |
|
| April 26, 2024 |
Exhibit 2.2 Description of Securities We were incorporated on January 14, 2020 as an exempted company with limited liability under the Companies Act (As Revised) of the Cayman Islands, or the “Cayman Islands Companies Act”. A Cayman Islands exempted company: ● is a company that conducts its business mainly outside the Cayman Islands; ● is prohibited from trading in the Cayman Islands with any pers |
|
| April 26, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ziqiang Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Jin Medical International Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements ma |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR THE SECURITIES ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 |
|
| April 26, 2024 |
Exhibit 15.4 December 11, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Jin Medical International Ltd. under its Form 6-K dated December 11, 2023. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of Jin Medical International Ltd. |
|
| April 26, 2024 |
JIN MEDICAL INTERNATIONAL LTD. UNDERWRITING AGREEMENT Exhibit 4.9 JIN MEDICAL INTERNATIONAL LTD. UNDERWRITING AGREEMENT March 27, 2023 Prime Number Capital, LLC 14 Myrtle Drive Great Neck, NY 11021 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, JIN MEDICAL INTERNATIONAL LTD., a Cayman Islands exempted company (the “Company”), hereby confirms its agreement (this “Agreement”) with the several und |
|
| April 26, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Jin Medical International Ltd. (the “Company”) on Form 20-F for the year ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Erqi Wang, Chief Executive Officer of the Company, |
|
| April 26, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Jin Medical International Ltd. (the “Company”) on Form 20-F for the year ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ziqiang Wang, Chief Financial Officer of the Compan |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu |
|
| April 12, 2024 |
Exhibit 16.1 April 12, 2024 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.W. Washington, DC 20549 Re: Jin Medical Technologies Ltd. Dear Sirs: We have read the statements made by Jin Medical Technologies Ltd. (the “Company”) in its Form 6-K filed with the Securities and Exchange Commission on April 12, 2024, which we take as a supplement to its Form 6-K fil |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of Chin |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| February 14, 2024 |
ZJYL / Jin Medical International Ltd. / Wang Erqi - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 JIN MEDICAL INTERNATIONAL LTD. (Name of Issuer) Ordinary Shares, Par Value $0.00005 Per Share (Title of Class of Securities) G5140V 112 (CUSIP Number) Erqi Wang No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China +86-519 896079 |
|
| February 14, 2024 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary s |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Registrant’s name) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of Chin |
|
| January 11, 2024 |
Exhibit 99.2 JIN MEDICAL INTERNATIONAL LTD. PROXY FOR 2024 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held at 9.30 a.m. Beijing Time on January 30, 2024 (8.30 p.m. Eastern Time on January 29, 2024) THE BOARD RECOMMENDS A VOTE FOR THE PROPOSALS. I. By way of an ordinary resolution, with effect from the date as determined by any director of the Company, being no later than March 31, 2024, t |
|
| January 11, 2024 |
Exhibit 99.1 JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To Be Held at 9.30 a.m. Beijing Time on January 30, 2024 (8.30 p.m. Eastern Time on January 29, 2024) (Record Date — January 12, 2024) To the Shareholders of Jin Medical International Ltd.: This notice |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 14, 2023 |
Exhibit 99.1 JIN MEDICAL INTERNATIONAL LTD. Enters into Memorandum of Understanding to Acquire Medical Equipment Sharing Platform Changzhou City, China, December 14, 2023 (GLOBE NEWSWIRE) - JIN MEDICAL INTERNATIONAL LTD. (the “Company” or “JinMed”) (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, tod |
|
| December 13, 2023 |
Exhibit 99.1 JIN MEDICAL INTERNATIONAL LTD. Empowers “Lao Le Hui” Assisted Bathing Project with Portable Nano-thermal Therapy Bath Changzhou City, China, December 13, 2023 (GLOBE NEWSWIRE) - JIN MEDICAL INTERNATIONAL LTD. (the “Company” or “JinMed”) (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, to |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 12, 2023 |
Exhibit 99.1 JIN MEDICAL INTERNATIONAL LTD. Secures RMB66 Million in Orders for Innovative Micro-Hyperbaric Oxygen Chamber Equipment Changzhou City, China, December 11, 2023 (GLOBE NEWSWIRE) - JIN MEDICAL INTERNATIONAL LTD. (the “Company” or “JinMed”) (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) No. 33 Lingxiang Road, Wujin District Changzhou City, Jiang |
|
| December 11, 2023 |
Exhibit 16.1 December 11, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Jin Medical International Ltd. under its Form 6-K dated December 11, 2023. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of Jin Medical International Ltd. |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China (Address of princi |
|
| August 23, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion of the financial condition and results of operations is based upon and should be read in conjunction with the unaudited financial results and statements of Jin Medical International Ltd. (the “Company,” “we,” “our,” or “us”) for the six (6) months ended March 31, 2023, furnished as Exhibit 99.1. to this report. Over |
|
| August 23, 2023 |
Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JIN MEDICAL INTERNATIONAL LTD. AND SUBSIDIARIES TABLE OF CONTENTS Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets as of March 31, 2023 and September 30, 2022 F-2 Unaudited Condensed Consolidated Statements of Comprehensive Income for the six months ended March 31, 2023 and 2022 F-3 Unaudit |
|
| April 6, 2023 |
Jin Medical International Ltd. Announces Exercise of the Underwriters’ Over-Allotment Option Exhibit 99.1 Jin Medical International Ltd. Announces Exercise of the Underwriters’ Over-Allotment Option Changzhou City, China, Apr. 6, 2023 – Jin Medical International Ltd. (the “Company” or “JinMed”) (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced that Prime Number Capital, LLC, a |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China (Address of princip |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-41661 JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China (Address of princip |
|
| March 31, 2023 |
Jin Medical International Ltd. Announces Pricing of $8,000,000 Initial Public Offering Exhibit 99.1 Jin Medical International Ltd. Announces Pricing of $8,000,000 Initial Public Offering Changzhou City, China, Mar. 27, 2023 – Jin Medical International Ltd. (the “Company” or “JinMed”) (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced the pricing of its initial public offe |
|
| March 31, 2023 |
Jin Medical International Ltd. Announces Closing of $8,000,000 Initial Public Offering Exhibit 99.2 Jin Medical International Ltd. Announces Closing of $8,000,000 Initial Public Offering Changzhou City, China, Mar. 30, 2023 – Jin Medical International Ltd. (the “Company” or “JinMed”) (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced the closing of its initial public offe |
|
| March 29, 2023 |
1,000,000 Ordinary Shares JIN MEDICAL INTERNATIONAL LTD. PROSPECTUS DATED March 27, 2023 Filed pursuant to Rule 424(b)(4) Registration No. 333-259767 1,000,000 Ordinary Shares JIN MEDICAL INTERNATIONAL LTD. We are offering 1,000,000 ordinary shares, par value US$0.001 per share (“Ordinary Shares”). This is the initial public offering of our Ordinary Shares. The offering price of our Ordinary Shares in this offering is $8.00 per share. Prior to the compl |
|
| March 23, 2023 |
March 23, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer |
|
| March 23, 2023 |
JIN MEDICAL INTERNATIONAL LTD. No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People’s Republic of China VIA EDGAR March 23, 2023 Ms. Jane Park U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Re: JIN MEDICAL INTERNATIONAL LTD. Registration Statement on Form F-1, |
|
| March 21, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 21, 2023 As filed with the U.S. Securities and Exchange Commission on March 21, 2023 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 13 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3790 Not Applicable (State or other ju |
|
| March 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables F-1 (Form Type) JIN MEDICAL INTERNATIONAL LTD. |
|
| March 7, 2023 |
March 7, 2023 Via Edgar Ms. Jane Park Division of Corporation Finance Office of Industrial Applications and Services U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 11 to Registration Statement on Form F-1 Filed February 24, 2023 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated March 2, 2023, from the staff (the “Staff”) of |
|
| March 7, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 7, 2023 As filed with the U.S. Securities and Exchange Commission on March 7, 2023 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 12 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3790 Not Applicable (State or other jur |
|
| February 24, 2023 |
As filed with the U.S. Securities and Exchange Commission on February 24, 2023 As filed with the U.S. Securities and Exchange Commission on February 24, 2023 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 11 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3790 Not Applicable (State or other |
|
| December 20, 2022 |
EX-FILING FEES 4 ea170537ex-feejinmedical.htm REGISTRATION FEE TABLE Exhibit 107 Calculation of Filing Fee Tables F-1 (Form Type) JIN MEDICAL INTERNATIONAL LTD. (Exact Name of Registrant as Specified in its Charter) (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount R |
|
| December 20, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 20, 2022 F-1/A 1 ea170537-f1a10jinmedical.htm AMENDMENT NO. 10 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on December 20, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 10 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified |
|
| December 1, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 1, 2022 F-1/A 1 ea169538-f1a9jinmedical.htm AMENDMENT NO. 9 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on December 1, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 9 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in i |
|
| December 1, 2022 |
December 1, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 8 to Registration Statement on Form F-1 Filed November 17, 2022 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated November 21, 2022, from the staff (the “Staff”) of the Securities and Exchan |
|
| December 1, 2022 |
Form of Underwriting Agreement*** Exhibit 1.1 JIN MEDICAL INTERNATIONAL LTD. UNDERWRITING AGREEMENT [?], 2022 Prime Number Capital LLC 14 Myrtle Drive Great Neck, NY 11021 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, JIN MEDICAL INTERNATIONAL LTD., a Cayman Islands exempted company (the ?Company?), hereby confirms its agreement (this ?Agreement?) with the several underwrit |
|
| November 17, 2022 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2022 F-1/A 1 ea168040-f1a8jinmedical.htm AMENDMENT NO. 8 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on November 17, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 8 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in |
|
| September 13, 2022 |
Form of Underwriting Agreement* EX-1.1 2 ea165658ex1-1jinmedical.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 JIN MEDICAL INTERNATIONAL LTD. UNDERWRITING AGREEMENT [●], 2022 Prime Number Capital LLC 14 Myrtle Drive Great Neck, NY 11021 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, JIN MEDICAL INTERNATIONAL LTD., a Cayman Islands exempted company (the “Company”), hereby |
|
| September 13, 2022 |
Employment Agreement by and between Ziqiang Wang (CFO) and the Registrant* EX-10.10 5 ea165658ex10-10jinmedical.htm EMPLOYMENT AGREEMENT BY AND BETWEEN ZIQIANG WANG (CFO) AND THE REGISTRANT Exhibit 10.10 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of [January14], [2020], by and between JIN MEDICAL INTERNATIONAL LTD., a company incorporated and existing under the laws of Cayman Islands (the “Company”), and [Ziqiang Wang ], an indiv |
|
| September 13, 2022 |
Form of Representative’s Warrant* EX-4.2 3 ea165658ex4-2jinmedical.htm FORM OF REPRESENTATIVE'S WARRANT Exhibit 4.2 Ordinary Shares Purchase Warrant JIN MEDICAL INTERNATIONAL LTD. Warrant Shares: [●] Initial Exercise Date: [●], 20[●] Issue Date: [●], 20[●] THIS ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Prime Number Capital LLC or its assigns (the “Holder”) are entitled, upon the terms and |
|
| September 13, 2022 |
CORRESP 1 filename1.htm September 13, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 6 to Registration Statement on Form F-1 Filed August 31, 2022 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated September 8, 2022, from the staff (the “Staff”) of t |
|
| September 13, 2022 |
Employment Agreement by and between Erqi Wang (CEO) and the Registrant* EX-10.1 4 ea165658ex10-1jinmedical.htm EMPLOYMENT AGREEMENT BY AND BETWEEN ERQI WANG (CEO) AND THE REGISTRANT Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of [January14], [2020], by and between JIN MEDICAL INTERNATIONAL LTD., a company incorporated and existing under the laws of Cayman Islands (the “Company”), and [Erqi Wang ], an individual (th |
|
| September 13, 2022 |
As filed with the U.S. Securities and Exchange Commission on September 13, 2022 F-1/A 1 ea165658-f1a7jinmedical.htm AMENDMENT NO. 7 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on September 13, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in |
|
| August 31, 2022 |
Form of Representative’s Warrant*** EX-4.2 3 ea165190ex4-2jinmedical.htm FORM OF REPRESENTATIVE'S WARRANT Exhibit 4.2 Ordinary Shares Purchase Warrant JIN MEDICAL INTERNATIONAL LTD.. Warrant Shares: [●] Initial Exercise Date: [●], 20[●] Issue Date: [●], 20[●] THIS ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Prime Number Capital LLC or its assigns (the “Holder”) are entitled, upon the terms an |
|
| August 31, 2022 |
August 31, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 5 to Registration Statement on Form F-1 Filed August 10, 2022 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated August 19, 2022, from the staff (the “Staff”) of the Securities and Exchange Co |
|
| August 31, 2022 |
Form of Underwriting Agreement*** EX-1.1 2 ea165190ex1-1jinmedical.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 JIN MEDICAL INTERNATIONAL LTD. UNDERWRITING AGREEMENT [●], 2022 Prime Number Capital LLC 14 Myrtle Drive Great Neck, NY 11021 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, JIN MEDICAL INTERNATIONAL LTD., a Cayman Islands exempted company (the “Company”), hereby |
|
| August 31, 2022 |
Form of Employment Agreement by and between executive officers and the Registrant*** EX-10.1 4 ea165190ex10-1jinmedical.htm FORM OF EMPLOYMENT AGREEMENT BY AND BETWEEN EXECUTIVE OFFICERS AND THE REGISTRANT Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), is entered into as of [MM/DD], [YYYY], by and between JIN MEDICAL INTERNATIONAL LTD., a company incorporated and existing under the laws of Cayman Islands (the “Company”), and [ ], an individual (the |
|
| August 31, 2022 |
As filed with the U.S. Securities and Exchange Commission on August 31, 2022 As filed with the U.S. Securities and Exchange Commission on August 31, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3790 Not Applicable (State or other ju |
|
| August 31, 2022 |
Form of Indemnification Agreement between the Registrant and its directors and officers* EX-10.2 5 ea165190ex10-2jinmedical.htm FORM OF INDEMNIFICATION AGREEMENT BETWEEN THE REGISTRANT AND ITS DIRECTORS AND OFFICERS Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of by and between JIN MEDICAL INTERNATIONAL LTD., a Cayman Islands company (the “Company”), and the undersigned, a director and/or an officer of the Company (“Indemn |
|
| August 31, 2022 |
Code of Business Conduct and Ethics of the Registrant* EX-14.1 6 ea165190ex14-1jinmedical.htm CODE OF BUSINESS CONDUCT AND ETHICS OF THE REGISTRANT Exhibit 14.1 CODE OF BUSINESS CONDUCT AND ETHICS OF JIN MEDICAL INTERNATIONAL LTD. INTRODUCTION Purpose This Code of Business Conduct and Ethics contains general guidelines for conducting the business of JIN MEDICAL INTERNATIONAL LTD., a Cayman Islands company (the “Company”), consistent with the highest s |
|
| August 10, 2022 |
As filed with the U.S. Securities and Exchange Commission on August 10, 2022 As filed with the U.S. Securities and Exchange Commission on August 10, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3790 Not Applicable (State or other ju |
|
| August 10, 2022 |
CORRESP 1 filename1.htm August 10, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 4 to Registration Statement on Form F-1 Filed July 15, 2022 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated July 26, 2022, from the staff (the “Staff”) of the Securi |
|
| July 15, 2022 |
As filed with the U.S. Securities and Exchange Commission on July 15, 2022 F-1/A 1 ea162835-f1a4jinmedical.htm AMENDMENT NO. 4 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on July 15, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its |
|
| July 15, 2022 |
CORRESP 1 filename1.htm July 15, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 3 to Registration Statement on Form F-1 Filed April 1, 2022 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated April 28, 2022, from the staff (the “Staff”) of the Securit |
|
| April 1, 2022 |
CORRESP 1 filename1.htm April 1, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 2 to Registration Statement on Form F-1 Filed February 4, 2022 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated March 1, 2022, from the staff (the “Staff”) of the Secur |
|
| April 1, 2022 |
As filed with the U.S. Securities and Exchange Commission on April 1, 2022 F-1/A 1 ea157345-f1a3jinmedical.htm AMENDMENT NO. 3 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on April 1, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its |
|
| February 4, 2022 |
EX-FILING FEES 3 ea154625ex-feejinmedical.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables F-1 (Form Type) JIN MEDICAL INTERNATIONAL LTD. (Exact Name of Registrant as Specified in its Charter) (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registe |
|
| February 4, 2022 |
As filed with the U.S. Securities and Exchange Commission on February 4, 2022 F-1/A 1 ea154625-f1a2jinmedical.htm AMENDMENT NO. 2 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on February 4, 2022 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in i |
|
| February 4, 2022 |
February 4, 2022 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 1 to Registration Statement on Form F-1 Filed December 10, 2021 File No. 333-259767 Dear Ms. Park: This letter is in response to the letter dated December 20, 2021, from the staff (the “Staff”) of the Securities and Exchan |
|
| December 10, 2021 |
CORRESP 1 filename1.htm December 10, 2021 Via Edgar Ms. Jane Park Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Registration Statement on Form F-1 Filed September 24, 2021 CIK No. 0001837821 Dear Ms. Park: This letter is in response to the letter dated November 16, 2021, from the staff (the “Staff”) of the Securities and |
|
| December 10, 2021 |
As filed with the U.S. Securities and Exchange Commission on December 10, 2021 F-1/A 1 ea151947-f1a1jinmedical.htm AMENDMENT NO. 1 TO FORM F-1 As filed with the U.S. Securities and Exchange Commission on December 10, 2021 Registration No. 333-259767 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in |
|
| September 24, 2021 |
EX-10.7 11 ea147457ex10-7jinmedical.htm SPOUSAL CONSENT Exhibit 10.7 Spousal Consent To Erhua Medical Technology (Changzhou) Co., Ltd: I [Chen Bai] (ID number: [220102196906123741]) am the legal spouse of Erqi Wang(ID number: [220104196806200079]). I hereby confirm that I know and unconditionally and irrevocably agree that Erhua Medical Technology (Changzhou) Co., Ltd. and Changzhou Erpu Investmen |
|
| September 24, 2021 |
Industry Report by Frost & Sullivan* Exhibit 99.1 Global, Japan and the PRC Wheelchair Industry P r e p a r e d f or ? 2020 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan. H i gh l y C on f i d e n t i a l June 2021 JIN MED |
|
| September 24, 2021 |
Memorandum and Articles of Association* EX-3.1 2 ea147457ex3-1jinmedical.htm MEMORANDUM AND ARTICLES OF ASSOCIATION Exhibit 3.1 MEMORANDUM AND ARTICLES OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL LTD. Incorporated on the 14th day of January, 2020 INCORPORATED IN THE CAYMAN ISLANDS Auth Code: G64625704351 www.verify.gov.ky THE COMPANIES LAW (2018 Revision) Company Limited by Shares MEMORANDUM OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL L |
|
| September 24, 2021 |
Share Disposal and Exclusive Option to Purchase Agreement* EX-10.5 9 ea147457ex10-5jinmedical.htm SHARE DISPOSAL AND EXCLUSIVE OPTION TO PURCHASE AGREEMENT Exhibit 10.5 股权处分及独家购买权合同 SHARE DISPOSAL AND EXCLUSIVE OPTION TO PURCHASE AGREEMENT 本股权处分及独家购买权合同（下称“本合同”）由以下各方于2020年11月26日在中华人民共和国（下称“中国”）常州市签订： This Share Disposal and Exclusive Option to Purchase Agreement (this “Agreement”) is executed by and among the following Parties as of November 26, 2020 in C |
|
| September 24, 2021 |
Form of Amended and Restated Memorandum and Articles of Association* EX-3.2 3 ea147457ex3-2jinmedical.htm FORM OF AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION Exhibit 3.2 THE COMPANIES ACT (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL LTD. (adopted by a Special Resolution passed on [ ] 2021 and effective immediately prior to the completion of the Company’s i |
|
| September 24, 2021 |
EX-10.8 12 ea147457ex10-8jinmedical.htm ENGLISH TRANSLATION OF THE SALES FRAMEWORK CONTRACT BETWEEN THE REGISTRANT AND NISSIN MEDICAL INDUSTRIES CO., LTD Exhibit 10.8 Changzhou Zhongjin Medical Co., Ltd.-Sales Framework Contract Sales Framework Contract No. : ZJRJXS-2017-001 Site of signing: Changzhou, Jiangsu, China Date of signing: January 5, 2017 供方（甲方）：常州中进医疗器材有限公司 Supplier (Party A): Changzho |
|
| September 24, 2021 |
Equity Interest Pledge Agreements* EX-10.4 8 ea147457ex10-4jinmedical.htm EQUITY INTEREST PLEDGE AGREEMENTS Exhibit 10.4 股权质押合同 EQUITY INTEREST PLEDGE AGREEMENT 本股权质押合同 （下称”本合同”）由下列各方于2020年11月26日在中华人民共和国（下称”中国”）常州市签订： This Equity Interest Pledge Agreement (this “Agreement”) has been executed by and among the following parties on November 26, 2020 in Changzhou, the People’s Republic of China (“China” or the “PRC”): 甲方： 尔华医疗科技（常州）有限公 |
|
| September 24, 2021 |
EX-10.9 13 ea147457ex10-9jinmedical.htm ENGLISH TRANSLATION OF THE RENTAL AGREEMENT BETWEEN THE REGISTRANT AND JIANGSU SHUANGZHENG VEHICLE INDUSTRY CO., LTD. DATED APRIL 20, 2014 Exhibit 10.9 Rental Agreement PARTIES (1) Jiangsu Shuangzheng Vehicle Industry Co., Ltd. is a corporation organized and existing under the laws of the P.R. China. (2) Zhongjin Medical Equipment (Taizhou) Co., Ltd. is an e |
|
| September 24, 2021 |
Exhibit 99.2 JIN MEDICAL INTERNATIONAL LTD No. 33 Lingxiang Road, Wujin District Changzhou City, Jiangsu Province People?s Republic of China Attn.: The board of directors Re: Consent of Frost & Sullivan (Beijing) Inc., Shanghai Branch Co. Dear Sirs, We understand that Jin Medical International Ltd (the ?Company?) has filed a draft registration statement (the ?Registration Statement?) with the Unit |
|
| September 24, 2021 |
Registrant’s Specimen Certificate for Ordinary Shares* EX-4.1 4 ea147457ex4-1jinmedical.htm REGISTRANT'S SPECIMEN CERTIFICATE FOR ORDINARY SHARES Exhibit 4.1 Share Certificate Number of certificate Number of shares JIN MEDICAL INTERNATIONAL LTD. COMPANY NUMBER [NUMBER] This is to certify that [Name] of [Address] is the registered holder of [Number] ordinary shares of [Value] each being [partly paid to the extent of [amount in words][amount in numerals |
|
| September 24, 2021 |
Consent of Oliver St. Clair Franklin* Exhibit 99.5 CONSENT OF OLIVER ST CLAIR FRANKLIN OBE JIN MEDICAL INTERNATIONAL LTD. (the ?Company?) intends to file a Registration Statement on Form F-1 (together with any amendments or supplements thereto, the ?Registration Statement?) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby co |
|
| September 24, 2021 |
As filed with the U.S. Securities and Exchange Commission on September 24, 2021 As filed with the U.S. Securities and Exchange Commission on September 24, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JIN MEDICAL INTERNATIONAL LTD. (Exact name of registrant as specified in its charter) Cayman Islands 3790 Not Applicable (State or other jurisdiction of incorpor |
|
| September 24, 2021 |
EX-99.3 18 ea147457ex99-3jinmedical.htm OPINION OF BEIJING DACHENG LAW OFFICE, LLP (SHANGHAI), PEOPLE'S REPUBLIC OF CHINA COUNSEL TO THE REGISTRANT, REGARDING CERTAIN PRC LAW MATTERS AND THE VALIDITY OF THE VIE AGREEMENTS Exhibit 99.3 北京大成（上海）律师事务所 Beijing Dacheng Law Offices,LLP (Shanghai) www.dentons.cn 上海市世纪大道100号环球金融中心9层、24层 (200120) 19th/24th Floor, Shanghai World Financial Center， 100 Centur |
|
| September 24, 2021 |
EX-99.4 19 ea147457ex99-4jinmedical.htm CONSENT OF JOURDAN B FRAIN Exhibit 99.4 CONSENT OF JOURDAN B FRAIN JIN MEDICAL INTERNATIONAL LTD. (the “Company”) intends to file a Registration Statement on Form F-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securit |
|
| September 24, 2021 |
Principal Subsidiaries and Consolidated Affiliated Entities* Exhibit 21.1 Principal Subsidiaries and Consolidated Affiliated Entities of the Registrant Subsidiaries Jurisdiction of incorporation or organization Zhongjin International Limited Hong Kong Erhua Medical Technology Chang Zhou Ltd. PRC VIE Changzhou Zhongjin Medical Equipment Co., Ltd. PRC VIE?s Subsidiaries Changzhou Zhongjin Jing?ao Trading Ltd. PRC Zhongjin Medical Equipment (Taizhou) Ltd. PRC |
|
| September 24, 2021 |
Exclusive Cooperation and Service Agreement* EX-10.3 7 ea147457ex10-3jinmedical.htm EXCLUSIVE COOPERATION AND SERVICE AGREEMENT Exhibit 10.3 独家业务合作及服务协议 EXCLUSIVE BUSINESS COOPERATION AND SERVICE AGREEMENT 本独家业务合作及服务协议（以下简称“本协议”）由以下各方于2020年11月26日在常州市签署： This Exclusive Business Cooperation and Service Agreement (this "Agreement") is entered into as of November 26, 2020 in Changzhou by and between the following parties: 甲方：尔华医疗科技（常州）有限公司 Party |
|
| September 24, 2021 |
September 24, 2021 Via Edgar Mr. Jason Drory Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Amendment No. 1 to Draft Registration Statement on Form F-1 Submitted June 30, 2021 CIK No. 0001837821 Dear Mr. Drory: This letter is in response to the letter dated July 16, 2021, from the staff (the “Staff”) of the Securities and |
|
| September 24, 2021 |
EX-99.6 21 ea147457ex99-6jinmedical.htm CONSENT OF JING CHEN Exhibit 99.6 CONSENT OF JING CHEN JIN MEDICAL INTERNATIONAL LTD. (the “Company”) intends to file a Registration Statement on Form F-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1 |
|
| September 24, 2021 |
EX-10.6 10 ea147457ex10-6jinmedical.htm PROXY AGREEMENT Exhibit 10.6 委托协议 Proxy Agreement 本委托协议(以下称“本协议”)于 2020年11月26日由以下各方在常州市签订： This Proxy Agreement (this “Agreement”) is made in Changzhou on November 26, 2020 among the following parties: 甲方 1：王尔琪 Party B 1: Erqi Wang 地址:上海市杨浦区学府街88弄8号802室 Address: Room 802, No. 8 Lane 88, Xuefu Road, Yangpu District, Shanghai 甲方 2：任震晴 Party B 2: Zhenqing Ren 地 |
|
| June 30, 2021 |
EX-10.7 3 filename3.htm Exhibit 10.7 Spousal Consent To Erhua Medical Technology (Changzhou) Co., Ltd: I [Chen Bai] (ID number: [220102196906123741]) am the legal spouse of Erqi Wang(ID number: [220104196806200079]). I hereby confirm that I know and unconditionally and irrevocably agree that Erhua Medical Technology (Changzhou) Co., Ltd. and Changzhou Erpu Investment Management Center (Limited Par |
|
| June 30, 2021 |
DRS/A 1 filename1.htm Confidential draft No. 2 as submitted to the Securities and Exchange Commission on June 30, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333-[●] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment to FORM F |
|
| June 30, 2021 |
EX-10.9 4 filename4.htm Exhibit 10.9 Rental Agreement PARTIES (1) Jiangsu Shuangzheng Vehicle Industry Co., Ltd. is a corporation organized and existing under the laws of the P.R. China. (2) Zhongjin Medical Equipment (Taizhou) Co., Ltd. is an enterprise engaged in the manufacture and sale of medical equipment which is also organized and existing under the laws of the P.R. China. The two parties h |
|
| June 30, 2021 |
EQUITY INTEREST PLEDGE AGREEMENT EX-10.4 2 filename2.htm Exhibit 10.4 股权质押合同 EQUITY INTEREST PLEDGE AGREEMENT 本股权质押合同 （下称”本合同”）由下列各方于2020年11月26日在中华人民共和国（下称”中国”）常州市签订： This Equity Interest Pledge Agreement (this “Agreement”) has been executed by and among the following parties on November 26, 2020 in Changzhou, the People’s Republic of China (“China” or the “PRC”): 甲方： 尔华医疗科技（常州）有限公司（简称”质权人”） Party A：Erhua Medical Technology（Chang |
|
| June 30, 2021 |
Exhibit 99.1 Global, Japan and the PRC Wheelchair Industry P r e p a r e d f or ? 2020 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan. H i gh l y C on f i d e n t i a l June 2021 JIN MED |
|
| June 30, 2021 |
DRSLTR 1 filename1.htm June 30, 2021 Via Edgar Mr. Jason Drory Division of Corporation Office of Life Sciences U.S. Securities and Exchange Commission Re: Jin Medical International Ltd. Draft Registration Statement on Form F-1 Submitted December 28, 2020 CIK No. 0001837821 Dear Mr. Drory: This letter is in response to the letter dated January 22, 2021, from the staff (the “Staff”) of the Securitie |
|
| December 28, 2020 |
SHARE DISPOSAL AND EXCLUSIVE OPTION TO PURCHASE AGREEMENT Exhibit 10.5 股权处分及独家购买权合同 SHARE DISPOSAL AND EXCLUSIVE OPTION TO PURCHASE AGREEMENT 本股权处分及独家购买权合同（下称“本合同”）由以下各方于2020年11月26日在中华人民共和国（下称“中国”）常州市签订： This Share Disposal and Exclusive Option to Purchase Agreement (this “Agreement”) is executed by and among the following Parties as of November 26, 2020 in Changzhou, the People’s Republic of China (“China” or the “PRC”): 甲方： 尔华医疗科技（常州）有限公司 Party A: Erhu |
|
| December 28, 2020 |
Exhibit 10.7 Changzhou Zhongjin Medical Co., Ltd.-Sales Framework Contract Sales Framework Contract No. : ZJRJXS-2017-001 Site of signing: Changzhou, Jiangsu, China Date of signing: January 5, 2017 供方（甲方）：常州中进医疗器材有限公司 Supplier (Party A): Changzhou Zhongjin Medical Co., Ltd. 需方（乙方）：日进医疗器株式会社 Buyer (Party B): Nissin Medical Instrument Co., Ltd. Party A and Party B are long-term business cooperation |
|
| December 28, 2020 |
EQUITY INTEREST PLEDGE AGREEMENT Exhibit 10.4 股权质押合同 EQUITY INTEREST PLEDGE AGREEMENT 本股权质押合同 （下称“本合同”）由下列各方于2020年11月26日在中华人民共和国（下称“中国”）常州市签订： This Equity Interest Pledge Agreement (this “Agreement”) has been executed by and among the following parties on November 26, 2020 in Changzhou, the People’s Republic of China (“China” or the “PRC”): 甲方： 尔华医疗科技（常州）有限公司（简称“质权人”） Party A：Erhua Medical Technology（Changzhou）Co.,Ltd (hereinafte |
|
| December 28, 2020 |
As confidentially submitted to the Securities and Exchange Commission on December 23, 2020. |
|
| December 28, 2020 |
EX-10.6 6 filename6.htm Exhibit 10.6 委托协议 Proxy Agreement 本委托协议(以下称“本协议”)于 2020年11月26日由以下各方在常州市签订： This Proxy Agreement (this “Agreement”) is made in Changzhou on November 26, 2020 among the following parties: 甲方 1：王尔琪 Party B 1: Erqi Wang 地址:上海市杨浦区学府街88弄8号802室 Address: Room 802, No. 8 Lane 88, Xuefu Road, Yangpu District, Shanghai 甲方 2：任震晴 Party B 2: Zhenqing Ren 地址: 江苏省泰州市海陵区南园新村172号 Address: No |
|
| December 28, 2020 |
??????????? EXCLUSIVE BUSINESS COOPERATION AND SERVICE AGREEMENT Exhibit 10.3 ??????????? EXCLUSIVE BUSINESS COOPERATION AND SERVICE AGREEMENT ?????????????????????????????2020?11?26???????? This Exclusive Business Cooperation and Service Agreement (this "Agreement") is entered into as of November 26, 2020 in Changzhou by and between the following parties: ????????????????? Party A: Erhua Medical Technology?Changzhou?Co.,Ltd ??? ????????????33? Address: No. 33 |
|
| December 28, 2020 |
Exhibit 99.1 |
|
| December 28, 2020 |
Exhibit 3.1 MEMORANDUM AND ARTICLES OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL LTD. Incorporated on the 14th day of January, 2020 INCORPORATED IN THE CAYMAN ISLANDS Auth Code: G64625704351 www.verify.gov.ky THE COMPANIES LAW (2018 Revision) Company Limited by Shares MEMORANDUM OF ASSOCIATION OF JIN MEDICAL INTERNATIONAL LTD. 1. The name of the Company is JIN MEDICAL INTERNATIONAL LTD.. 2. The Reg |
